Legal status · United States
Is NNZ-2591 legal in the United States?
No. NNZ-2591 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
NNZ-2591 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| FDA approval status | Investigational; Phase 3 (Fast Track, Orphan) |
| Evidence level | Preliminary (research strength: Moderate) |
| Reviewed | Sep 2026 |
Classification and note come from the NNZ-2591 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
NNZ-2591 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What NNZ-2591 is
An oral IGF-1 metabolite mimic from the makers of trofinetide (Daybue), in the first-ever Phase 3 for Phelan-McDermid syndrome since February 2026.
NNZ-2591 is a synthetic analog of cyclic glycine-proline, a natural IGF-1 metabolite, and a sister molecule to trofinetide, which Neuren took to approval for Rett syndrome. It carries Fast Track, Orphan and Rare Pediatric designations.
Mechanism: Normalizes IGF-1 and synaptic signaling in the brain, improving neuronal connectivity in neurodevelopmental disorders.
Regulatory history: Investigational; Phase 3 (Fast Track, Orphan)
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for NNZ-2591 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
NNZ-2591 in other countries
Frequently asked questions
Is NNZ-2591 legal in the United States?
No. NNZ-2591 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Can I buy NNZ-2591 in the United States?
No approved product exists to buy. In the United States NNZ-2591 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is NNZ-2591 FDA approved?
No. FDA status: Investigational; Phase 3 (Fast Track, Orphan). Current US classification: "Investigational, not approved". Evidence level: Preliminary.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for NNZ-2591 live on its compound profile.
NNZ-2591 profileThis page is general information about the regulatory status of NNZ-2591 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.